Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan.
Hum Vaccin Immunother. 2021 Mar 4;17(3):836-837. doi: 10.1080/21645515.2020.1801318. Epub 2020 Sep 22.
The Coronavirus Disease 2019 (COVID-19) pandemic has been growing, including in Japan where it has been estimated that as many as 3.1% of patients positive for new CoV strain SARS-CoV-2 might die of COVID-19-related respiratory failure. Meanwhile, human papillomavirus (HPV) is spreading in Japan. The fatality rate for HPV-associated cancers after infection with HPV is as much as that for COVID-19 in Japan, although the time to disease is much longer for HPV. Among advanced countries, the cervical cancer screening rate in Japanese females is very low. The Japanese Ministry of Health, Labor and Welfare (MHLW) suspended its official recommendation for HPV vaccination in June 2013 due to alleged adverse post-vaccination events in several young girls, such as chronic pain and motor impairment, which were repeatedly reported in the media. Subsequently, the rate for vaccinating girls plummeted from approximately 70% to the current rate of 1% or less. Women should accept HPV vaccination for the eventual prevention of cervical cancer with the same passion they are for COVID-19 testing.
新型冠状病毒病 2019（COVID-19）大流行正在加剧，包括在日本，据估计，多达 3.1%的新型冠状病毒株 SARS-CoV-2 检测呈阳性的患者可能因 COVID-19 相关呼吸衰竭而死亡。与此同时，人乳头瘤病毒（HPV）在日本传播。感染 HPV 后，HPV 相关癌症的死亡率与日本的 COVID-19 相当，尽管 HPV 的发病时间要长得多。在发达国家中，日本女性的宫颈癌筛查率非常低。由于几名年轻女孩反复在媒体上报告接种疫苗后的慢性疼痛和运动障碍等所谓的不良事件，日本厚生劳动省（MHLW）于 2013 年 6 月暂停了 HPV 疫苗接种的官方建议。随后，女孩接种疫苗的比例从大约 70%骤降至目前的 1%或更低。女性应该像对待 COVID-19 检测一样，积极接受 HPV 疫苗接种，以最终预防宫颈癌。
